Radioimmunotherapy for treatment of acute myeloid leukemia

CA3329371A1Undetermined Publication Date: 2025-11-06RGT UNIV OF CALIFORNIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CA3329371
Authority / Receiving Office
CA · CA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-04-28
Filing Date
2025-04-28
Publication Date
2025-11-06
Patent Text Reader

Abstract

Provided are radioimmunoconjugates comprising an antibody that specifically bind to the activated form of integrin β 2 ; a radionuclide which may be an alpha emitter or a beta emitter such as 225 Ac; and a chelator such as Macropa, and derivatives thereof, wherein the chelator chelates to radionuclide, and wherein the chelator is coupled to the antibody through a link comprising poly(ethylene glycol) moieties and methods of using the radioimmunoconjugates for treating cancer and for detecting cancer cells.
Need to check novelty before this filing date? Find Prior Art